The latest results for chicken feed additive developer Phosphagenics are anything but ‘poultry’.

The developer, which identifies benefits for chickens with its Vitamin E based drug delivery system, hopes to tap into the $180 billion global poultry feed market, with feed additives that improve the efficiency of bird growth, laying capacity and disease prevention.

The company’s latest study of Australian broilers – the white chickens bred specifically for meat production – suggest its patented Tocopheryl Phosphate Mixture (TPM) negated the impact of heat stress which can reduce growing rates by up to 5 per cent.

TPM is derived from Vitamin E and enhances the solubility and absorption of drugs and nutrients.

But chickens aren’t the only animals that stand to benefit. TPM’s potential has been tested in pigs and cattle too. Further studies are ongoing and there is potential for the human market in patches, gels and injectables, the company says.

Phosphagenics (ASX:POH) gained 6 per cent on Friday to close at 1.7c, heights it hasn’t reached since the end of February.

POH shares over the past year. Source:

“To date we have demonstrated significant utility and value for TPM in both the pig and poultry feed sector,” said chief executive Dr Ross Murdoch.

“Discussions with key potential partners have highlighted poultry as a key species of interest, increasing the importance of this result.

“This trial further reinforces our previous strong data and adds a new driver for TPM’s inclusion in the lucrative poultry feed market.”

Earlier this month Phosphagenics signed a licensing agreement for the products use in personal care from multinational Rodan and Fields.

Its last half year report showed revenues down 38 per cent at $813,000, with $4 million left in the bank at the end of September.